Pacira News

This is selected news for Pacira, which is filed under Sectors / Healthtech. There are 2.8K news items for this page. Pacira is occasionally combined with Dave Stack, Frontier Capital and Stephens Investment Management in news items.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
9/24/2022 Pacira BioSciences (NASDAQ:PCRX) Earns Outperform Rating from Wedbush
Wedbush reissued their outperform rating on shares of Pacira BioSciences ( NASDAQ:PCRX ‚Ai Get Rating ) in a research report report published on Wednesday, RTT News reports. The firm currently has a $94.00 price target on the stock. PCRX has been the subject of a number of other research reports. Needham ...
theenterpriseleader.com
9/22/2022 Oncogene Inhibitors Market is expected to grow by 7.70% during the forecast period to 2029 - Digital Journal
... sample/?dbmr=global-oncogene-inhibitors-market Some of the major players operating in the oncogene inhibitors market are AstraZeneca, Merck Sharp & Dohme Corp., Pfizer Inc, CELGENE CORPORATION, AKRON, Inc., Novartis AG, Galen Limited., Pacira BioSciences, Inc, Johnson & Johnson Services , Inc. , Fresenius Kabi AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited ...
digitaljournal.com
9/22/2022 Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Ticker Report
Pacira BioSciences, Inc. ( NASDAQ:PCRX ‚Ai Get Rating ) has been given a consensus rating of ‚AuModerate Buy‚Au by the ten analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the ...
Ticker Report
9/22/2022 Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Pacira BioSciences, Inc. (NASDAQ:PCRX ‚Ai Get Rating) has been given a consensus rating of ‚AuModerate Buy‚Au by the ten analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the ...
baseballnewssource.com
9/21/2022 Pacira BioSciences Announces Positive Topline Data from
... statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- -- Company on track to submit supplemental New Drug Application in first quarter of 2023 -- TAMPA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and ...
Globe Newswire
9/21/2022 Pacira BioSciences Announces Positive Topline Data from Globe Newswire
9/21/2022 Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy Yahoo News
9/21/2022 Pacira BioSciences Reports Positive Topline Data From Phase 3 Study Of EXPAREL Nasdaq
9/21/2022 Pacira BioSciences Reports Positive Topline Data From Phase 3 Study Of EXPAREL | Markets Insider Business Insider
9/21/2022 Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy | Insider Tracking insidertracking.com
9/21/2022 2022-09-21 | NDAQ:PCRX | Press Release | Pacira BioSciences Inc. stockhouse.com
9/21/2022 Pacira Biosciences Inc. (PCRX) Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy researchpool.com
9/20/2022 Pacira Receives Positive CHMP Opinion for EXPAREL® for the Globe Newswire
9/20/2022 2022-09-20 | NDAQ:PCRX | Press Release | Pacira BioSciences Inc. stockhouse.com
9/20/2022 Pacira Biosciences Inc. (PCRX) Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older researchpool.com
9/16/2022 Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028 sbwire.com
9/16/2022 Liposomal Drugs Market is Expected to Grow at a CAGR of 13.20% during the Forecast Period - Digital Journal digitaljournal.com
9/15/2022 Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Gradient Investments LLC com-unik.info
9/15/2022 Gradient Investments LLC Sells 18,632 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) thelincolnianonline.com
9/14/2022 Walleye Capital LLC Purchases 19,930 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - The Cerbat Gem thecerbatgem.com
9/13/2022 Pacira BioSciences Reports Preliminary Net Product Sales of Globe Newswire
9/13/2022 2022-09-13 | NDAQ:PCRX | Press Release | Pacira BioSciences Inc. stockhouse.com
9/13/2022 Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022 - ForexTV forextv.com
9/13/2022 Rock Springs Capital Management LP Sells 1,000,000 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Daily Political
9/13/2022 Rock Springs Capital Management LP Sells 1,000,000 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - WKRB News wkrb13.com